MLYS Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Mineralys Therapeutics, Inc.'s net margin of 6.29%. Mineralys Therapeutics, Inc.'s return on equity of -51.62% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.

Mineralys Therapeutics, Inc. has a consensus price target of $50.88, signalling upside risk potential of 35.76%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $64.08 which suggests that it could fall by -5.98%. Given that Mineralys Therapeutics, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Mineralys Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Mineralys Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.

Mineralys Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Mineralys Therapeutics, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Mineralys Therapeutics, Inc.'s net income of -$36.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Mineralys Therapeutics, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics, Inc. is -- versus 10.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Mineralys Therapeutics, Inc.'s net margin of -259.95%. Mineralys Therapeutics, Inc.'s return on equity of -51.62% beat Insmed, Inc.'s return on equity of -193.23%.

Mineralys Therapeutics, Inc. has a consensus price target of $50.88, signalling upside risk potential of 35.76%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 22.84%. Given that Mineralys Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Mineralys Therapeutics, Inc. is more attractive than Insmed, Inc..

Mineralys Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Mineralys Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Mineralys Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Mineralys Therapeutics, Inc.'s net income of -$36.9M is higher than Insmed, Inc.'s net income of -$370M. Notably, Mineralys Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics, Inc. is -- versus 74.41x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Mineralys Therapeutics, Inc.'s net margin of -39.75%. Mineralys Therapeutics, Inc.'s return on equity of -51.62% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Mineralys Therapeutics, Inc. has a consensus price target of $50.88, signalling upside risk potential of 35.76%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 2.11%. Given that Mineralys Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Mineralys Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Mineralys Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Mineralys Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Mineralys Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Mineralys Therapeutics, Inc.'s net income of -$36.9M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Mineralys Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics, Inc. is -- versus 17.70x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Mineralys Therapeutics, Inc.'s net margin of -301.29%. Mineralys Therapeutics, Inc.'s return on equity of -51.62% beat Nektar Therapeutics's return on equity of -327.67%.

Mineralys Therapeutics, Inc. has a consensus price target of $50.88, signalling upside risk potential of 35.76%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 144.3%. Given that Nektar Therapeutics has higher upside potential than Mineralys Therapeutics, Inc., analysts believe Nektar Therapeutics is more attractive than Mineralys Therapeutics, Inc..

Mineralys Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.

Mineralys Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mineralys Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Mineralys Therapeutics, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Mineralys Therapeutics, Inc.'s net income of -$36.9M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Mineralys Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mineralys Therapeutics, Inc. is -- versus 48.30x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.